Membranous nephropathy

被引:0
作者
Hoxha, Elion [1 ]
Huber, Tobias B. [1 ]
机构
[1] Univ Klinikum Hamburg Eppendorf, Zentrum Innere Med, Med Klin 3, Martinistr 52, D-20246 Hamburg, Germany
来源
NEPHROLOGIE | 2025年 / 20卷 / 01期
关键词
Glomerul & auml; re Basalmembran; Nephrotisches Syndrom; PLA2R1; Autoantik & ouml; rper; Antigens; DOMAIN-CONTAINING; 7A; PHOSPHOLIPASE-A2; RECEPTOR; AUTOANTIBODIES; ANTIBODIES; RITUXIMAB; ELISA;
D O I
10.1007/s11560-024-00806-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Membranous nephropathy (MN) is the most frequent cause of a nephrotic syndrome in nondiabetic adults. The disease is caused when circulating antibodies are deposited on the epithelial side of the glomerular basement membrane. These autoantibodies are directed against antigens that are expressed or deposited on the glomerular podocytes. In 80% of patients with MN the antigen responsible for disease development is phospholipase A2 receptor 1 (PLA2R1). In recent years a large number of other (potential) autoantibodies have been reported, which could be responsible for the development of MN. An antigen-specific diagnosis of MN is important for the differential diagnosis in these patients as the incidence of specific diseases, most importantly tumors, differs greatly depending on the responsible autoantigen. For this reason the identification of the specific antigen influences the differential diagnostics in patients with MN. The PLA2R1 antibody level is important for an individualized treatment management and is highly relevant for the long-term prognosis of patients with MN. The identification of further potential autoantigens in patients with MN enables the implementation of similar ground-breaking developments in the diagnostics and treatment possibilities of MN, also in patients with non-PLA2R1-induced MN. The elucidation of the antigen-specific pathogenesis of MN represents the foundation for the development of novel, more specific curative treatment options.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 28 条
  • [1] Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers
    Avasare, Rupali S.
    Clark, Samantha
    Spain, Rebecca I.
    Wusirika, Raghav
    Rope, Robert
    Gurley, Susan
    Stanaway, Madison
    Sekulic, Miroslav
    Santoriello, Dominick
    Bomback, Andrew S.
    Canetta, Pietro
    Iyer, Sitalakshmi J.
    Kung, Vanderlene
    Charu, Vivek
    Troxell, Megan L.
    Kudose, Satoru
    Andeen, Nicole K.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 9 (05): : 1379 - 1386
  • [2] Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
    Barbour, Sean J.
    Fervenza, Fernando C.
    Induruwage, Dilshani
    Brenchley, Paul E.
    Rovin, Brad
    Hladunewich, Michelle A.
    Reich, Heather N.
    Lafayette, Richard
    Aslam, Nabeel
    Appel, Gerald B.
    Zand, Ladan
    Kiryluk, Krzysztof
    Liu, Lili
    Cattran, Daniel C.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1283 - 1293
  • [3] M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
    Beck, Laurence H., Jr.
    Bonegio, Ramon G. B.
    Lambeau, Gerard
    Beck, David M.
    Powell, David W.
    Cummins, Timothy D.
    Klein, Jon B.
    Salant, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01) : 11 - 21
  • [4] Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy A Validation Study
    Bobart, Shane A.
    Han, Heedeok
    Tehranian, Shahrzad
    De Vriese, An S.
    Roman, Juan Carlos Leon
    Sethi, Sanjeev
    Zand, Ladan
    Andrades Gomez, Cristina
    Giesen, Callen D.
    Soler, Maria Jose
    Bomback, Andrew S.
    Fervenza, Fernando C.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (12): : 1833 - 1839
  • [5] NELL1 is a target antigen in malignancy-associated membranous nephropathy
    Caza, Tiffany N.
    Hassen, Samar I.
    Dvanajscak, Zeljko
    Kuperman, Michael
    Edmondson, Rick
    Herzog, Christian
    Storey, Aaron
    Arthur, John
    Cossey, L. Nicholas
    Sharma, Shree G.
    Kenan, Daniel J.
    Larsen, Christopher P.
    [J]. KIDNEY INTERNATIONAL, 2021, 99 (04) : 967 - 976
  • [6] Primary Membranous Nephropathy
    Couser, William G.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (06): : 983 - 997
  • [7] Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
    Dahan, Karine
    Debiec, Hanna
    Plaisier, Emmanuelle
    Cachanado, Marine
    Rousseau, Alexandra
    Wakselman, Laura
    Michel, Pierre-Antoine
    Mihout, Fabrice
    Dussol, Bertrand
    Matignon, Marie
    Mousson, Christiane
    Simon, Tabassome
    Ronco, Pierre
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (01): : 348 - 358
  • [8] Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
    Fervenza, F. C.
    Appel, G. B.
    Barbour, S. J.
    Rovin, B. H.
    Lafayette, R. A.
    Aslam, N.
    Jefferson, J. A.
    Gipson, P. E.
    Rizk, D. V.
    Sedor, J. R.
    Simon, J. F.
    McCarthy, E. T.
    Brenchley, P.
    Sethi, S.
    Avila-Casado, C.
    Beanlands, H.
    Lieske, J. C.
    Philibert, D.
    Li, T.
    Thomas, L. F.
    Green, D. F.
    Juncos, L. A.
    Beara-Lasic, L.
    Blumenthal, S. S.
    Sussman, A. N.
    Erickson, S. B.
    Hladunewich, M.
    Canetta, P. A.
    Hebert, L. A.
    Leung, N.
    Radhakrishnan, J.
    Reich, H. N.
    Parikh, S. V.
    Gipson, D. S.
    Lee, D. K.
    da Costa, B. R.
    Juni, P.
    Cattran, D. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 36 - 46
  • [9] Membranous Nephropathy: A Journey From Bench to Bedside
    Francis, Jean M.
    Beck, Laurence H., Jr.
    Salant, David J.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (01) : 138 - 147
  • [10] False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy
    Hoxha, Elion
    Reinhard, Linda
    Castedello, Thomas
    Becker, Jan U.
    [J]. KIDNEY INTERNATIONAL, 2023, 103 (02) : 411 - 415